28033-32-1

Usage

Uses

Used in Pharmaceutical Research:
4-(2-Methoxyphenoxy)piperidine is used as a building block for the synthesis of heterocyclic compounds with potential biological activity, serving as a crucial component in the development of new drug candidates and pharmacological agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-(2-Methoxyphenoxy)piperidine is utilized as a key intermediate for the creation of novel compounds with therapeutic potential, contributing to the advancement of drug discovery and design.
Used in Drug Development:
4-(2-Methoxyphenoxy)piperidine is employed as a precursor in the synthesis of new drug candidates, playing a significant role in the exploration of its properties and potential applications, which are essential for further chemical and pharmacological studies.

InChI:InChI=1/C12H17NO2/c1-14-11-4-2-3-5-12(11)15-10-6-8-13-9-7-10/h2-5,10,13H,6-9H2,1H3

Upstream product

• 90-05-1 2-methoxy-phenol 
• 944808-11-1 tert-butyl 4-(2-methoxyphenoxy)piperidine-1-carboxylate 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 253603-59-7 1-benzyl-4-(2-methoxyphenoxy)piperidine 

Relevant academic research and scientific papers

DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS

Compounds of formula I: I are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS

The present invention relates to derivatives of general formula I wherein : - W represents nitrogen, - R1 represents: ? a hydrogen or a linear or branched C1-C5 alkyl radical or, ? a C1-C3 alkyl radical substituted with groups such as trifluoromethyl, nitrile, hydroxy, C1-C3 alcoxy, C3-C6 alkoxyalkoxy, indolyl, thiophenyl, oxothiophenyl, C1-C3 N-alkylcarbamoyl groups or, ? a phenyl or pyridyl or naphthyl, or thiophenyl group optionally substituted with one or more groups such as halogen atoms, nitro, nitrile, trifluoromethyl, vinyl, methylsulfanyl, linear branched C1-C4 alkyl, linear or branched C1-C3 alkoxy groups, ? a C6 2-oxocycloalkyl radical - R2 represents a methyl or heptyl, - m, n are equal to 1, - V represents CH2, - X-Y represents -N- (C=O) -, -CH-O-, - Z represents a phenyl group substituted with one or more trifluoromethyl groups, halogen atoms or linear C1-C4 alkyl groups.

2-(Aryloxy)ethylamine derivatives: Ring opened congeners of long chain 1-arylpiperazines with high 5-HT(1A) receptor affinity and selectivity versus D2 and α1 receptors

1-Aryl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1- yl)propyl]piperazine derivatives, previously reported as 5-HT(1A)/D2 ligands, were modified by opening the piperazine ring. Twenty-two ring opened congeners were prepared and their affinity for serotonin 5-HT(1A), dopamine D2, and α1-adrenergic receptors was measured in vitro. Among the herein reported compounds, the 2(aryloxy)ethylamine derivatives 38-40, 43 and 44 displayed 5-HT(1A) receptor affinity in the nanomolar range. In particular, compound 44 was found to be a potent and selective 5-HT(1A) ligand (K(i)= 0.71 nM), completely devoid of D2 and α1 receptor binding affinity. Our data indicate that removal of the ethylene chain of the piperazine ring, together with an isosteric substitution, can lead to ligand with high 5- HT(1A) receptor affinity and selectivity. Furthermore, compounds 40 and 44 were submitted to the [35S]GTPγS binding assay for a preliminary evaluation of their intrinsic activity on the 5-HT(1A) receptor.